Skip to main content

Advertisement

Table 1 Patients and their clinico-pathological characteristics

From: An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients

Characteristic No. of patients %
All patients 45 100 %
Time between primary surgery and CTC sampling (DFI)   
  ≤ 5 years 16 36 %
  > 5 years 21 47 %
 Primary not removed 8 18 %
Age at CTC sampling   
  ≤ 50 years 4 9 %
  > 50 years 41 91 %
Menopausal status   
 Premenopausal 2 4 %
 Postmenopausal 43 96 %
Histologic grade (Bloom-Richardson)   
 I, well differentiated 5 11 %
 II, moderately differentiated 23 51 %
 III, poorly differentiated 4 9 %
 Unknown 13 29 %
Pathological tumor size   
 pT1, ≤2 cm 20 44 %
 pT2-4, >2 cm 22 49 %
 Unknown 3 7 %
Lymph nodes involved   
 No 14 31 %
 Yes 27 60 %
 Unknown 4 9 %
ERa statusa   
 Negative 1 2 %
 Positive 44 98 %
PgR statusa   
 Negative 5 11 %
 Positive 36 80 %
 Unknown 4 9 %
HER2/neu statusa   
 Negative 37 82 %
 Positive 3 7 %
 Unknown 5 11 %
Histological type   
 Lobular 13 29 %
 Ductal 28 62 %
 Ductolobular 3 7 %
 Ductal, signet-cell 1 2 %
Adjuvant chemotherapy   
 No 31 69 %
 Yes 14 31 %
Adjuvant hormonal therapy   
 No 24 53 %
 Yes 21 47 %
Any adjuvant therapy   
 No 22 49 %
 Yes 23 51 %
Site of metastasis   
 Visceral 5 11 %
 Non-visceral 26 58 %
 Both 14 31 %
1st line treatment   
 Anastrozol 15 33 %
 Letrozol 16 36 %
 Exemestane 14 31 %
Median progression-free survival (PFS in days; range)b 358 (14–1255)  
Median baseline CTC count (range in 7.5 mL blood) 8 (0–32,492)  
  1. aAs retrieved from pathology reports
  2. bAlso includes censoring data from patients censored at last follow-up date